Wedbush reissued their buy rating on shares of Immunic (NASDAQ:IMUX) in a report issued on Sunday morning, TipRanks reports. Wedbush currently has a $58.00 price target on the stock.
A number of other equities research analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Immunic from a buy rating to a hold rating in a research report on Tuesday, June 23rd. Roth Capital assumed coverage on shares of Immunic in a research note on Wednesday, March 25th. They set a buy rating and a $44.00 price objective for the company. HC Wainwright reissued a buy rating and set a $45.00 price objective on shares of Immunic in a research note on Tuesday, June 16th. Finally, ValuEngine cut shares of Immunic from a strong-buy rating to a buy rating in a research note on Monday, May 11th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Immunic currently has an average rating of Buy and an average target price of $39.80.
IMUX stock opened at $12.11 on Friday. The firm has a 50 day moving average of $12.52 and a 200-day moving average of $9.34. Immunic has a 12-month low of $4.19 and a 12-month high of $17.24. The company has a market cap of $183.66 million, a price-to-earnings ratio of -3.28 and a beta of 3.17.
Several institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN grew its stake in Immunic by 78.9% in the 1st quarter. Wells Fargo & Company MN now owns 10,814 shares of the company’s stock worth $65,000 after acquiring an additional 4,769 shares during the period. Renaissance Technologies LLC grew its stake in Immunic by 44.3% in the 4th quarter. Renaissance Technologies LLC now owns 60,631 shares of the company’s stock worth $588,000 after acquiring an additional 18,602 shares during the period. Finally, International Biotechnology Trust PLC purchased a new stake in Immunic in the 2nd quarter worth approximately $1,531,000. 14.41% of the stock is owned by institutional investors and hedge funds.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
See Also: What is Call Option Volume?
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.